2 weeks Ago By Defense World Staff
Elevance Health (NYSE:ELV – Free Report) had its price target upped by Barclays from $512.00 to $522.00 in a research note released on Wednesday,Benzinga reports.
The firm currently has an overweight rating on the stock.Several other research analysts also recently commented on ELV. Robert W.
Baird reissued a “neutral” rating and issued a $529.00 price target (down from $625.00) on shares of Elevance Health in a report on Tuesday, April 15th.
Argus raised Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price objective for the company in a research note on Monday, March 17th. StockNews.
com upgraded Elevance Health from a “hold” rating to a “buy” rating in a research note on Thursday, March 20th. Guggenheim initiated coverage on Elevance Health in a research report on Wednesday, April 9th. They set a “buy” rating and a $518.
00 price target for the company. Finally, Baird R W downgraded shares of Elevance Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, April 15th. Four investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock.
Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $509.44.
Read Our Latest Stock Analysis on Elevance HealthElevance Health Price PerformanceELV opened at $421.55 on Wednesday. The firm has a 50-day moving average price of $420.
00 and a 200-day moving average price of $408.48. Elevance Health has a twelve month low of $362.
21 and a twelve month high of $567.26. The company has a quick ratio of 1.
50, a current ratio of 1.45 and a debt-to-equity ratio of 0.71.
The company has a market capitalization of $95.43 billion, a price-to-earnings ratio of 16.46, a PEG ratio of 1.
18 and a beta of 0.77. Elevance Health (NYSE:ELV – Get Free Report) last posted its earnings results on Tuesday, April 22nd.
The company reported $11.97 earnings per share (EPS) for the quarter, topping the consensus estimate of $10.60 by $1.
37. Elevance Health had a return on equity of 18.28% and a net margin of 3.
38%. The firm had revenue of $48.77 billion for the quarter, compared to the consensus estimate of $46.
26 billion. Equities analysts expect that Elevance Health will post 33.96 EPS for the current year.
Elevance Health Announces DividendThe company also recently announced a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be given a $1.71 dividend.
The ex-dividend date of this dividend is Tuesday, June 10th. This represents a $6.84 annualized dividend and a yield of 1.
62%. Elevance Health’s payout ratio is 26.71%.
Insider Transactions at Elevance HealthIn other news, EVP Charles Morgan Kendrick, Jr. sold 3,504 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $396.
30, for a total transaction of $1,388,635.20. Following the completion of the transaction, the executive vice president now directly owns 10,116 shares in the company, valued at approximately $4,008,970.
80. This represents a 25.73 % decrease in their position.
The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of Elevance Health stock in a transaction on Monday, March 10th.
The stock was sold at an average price of $415.13, for a total transaction of $183,902.59.
Following the completion of the transaction, the chief accounting officer now directly owns 1,847 shares of the company’s stock, valued at $766,745.11. The trade was a 19.
34 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,535 shares of company stock worth $3,521,612 in the last quarter.
Company insiders own 0.29% of the company’s stock. Institutional Investors Weigh In On Elevance HealthSeveral institutional investors have recently made changes to their positions in ELV.
Accredited Wealth Management LLC purchased a new stake in shares of Elevance Health during the fourth quarter valued at $25,000. Flagship Wealth Advisors LLC purchased a new stake in Elevance Health during the fourth quarter worth $26,000. OFI Invest Asset Management purchased a new stake in shares of Elevance Health during the 4th quarter worth $29,000.
WealthTrak Capital Management LLC purchased a new position in Elevance Health in the fourth quarter valued at about $29,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of Elevance Health during the fourth quarter valued at about $30,000.
Institutional investors own 89.24% of the company’s stock. Elevance Health Company Profile (Get Free Report)Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States.
The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.See AlsoFive stocks we like better than Elevance HealthWhat is Insider Trading? What You Can Learn from Insider TradingShort Sellers Gave Up on These 3 Names RecentlyHow Technical Indicators Can Help You Find Oversold Stocks 3 Boring Stocks Outperforming the Market This YearCD Calculator: Certificate of Deposit Calculator If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy.
